Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (4)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Yoshii, T.
Right arrow Articles by Komori, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yoshii, T.
Right arrow Articles by Komori, T.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy (2001) 47, 631-637
© 2001 The British Society for Antimicrobial Chemotherapy

Therapeutic possibilities of long-term roxithromycin treatment for chronic diffuse sclerosing osteomyelitis of the mandible

Takashi Yoshiia,*, Hidetaka Nishimurab, Tomohiro Yoshikawab, Shungo Furudoib, Ayumi Yoshiokab, Iwao Takenonob, Yoshiki Ohtsukab and Takahide Komorib

a Department of Dentistry, Hyogo Prefectural Staff Health Center 5-10-1, Shimoyamate-dori, Chuo-ku, Kobe, Hyogo 650-8567; b Department of Oral and Maxillofacial Surgery, Kobe University School of Medicine, Kobe, Japan

The clinical efficacy of long-term roxithromycin treatment was examined objectively in nine patients with chronic diffuse sclerosing osteomyelitis of the mandible. Roxithromycin was administered orally at a dose of 300 mg/day for between 68 days and 66 months. In seven of the nine cases (77.8%), the symptoms disappeared 1–12 months after the start of therapy. Radiography showed that osteolytic changes (evident from ‘moth-eaten’ appearance of bone) had improved but that osteosclerosis had persisted or become more predominant by the end of therapy. Therefore, the optimum duration of treatment should be decided according to the amelioration of symptoms along with the disappearance of osteolytic findings in radiographs. Diarrhoea and stomach discomfort occurred in one case, and liver dysfunction in another, but these adverse reactions were relatively mild. The mechanism of action of roxithromycin in this study is not yet fully understood, but our results indicate that long-term roxithromycin treatment may be useful for diffuse sclerosing osteomyelitis of the mandible and should be attempted before surgical treatment is considered.

* Corresponding author. Tel: +81-78-362-382; Fax: +81-78-362-4470; E-mail: takashi3{at}basil.ocn.ne.jp


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
J Antimicrob ChemotherHome page
G. W. Amsden
Anti-inflammatory effects of macrolides--an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions?
J. Antimicrob. Chemother., January 1, 2005; 55(1): 10 - 21.
[Abstract] [Full Text] [PDF]


Home page
Rheumatology (Oxford)Home page
Y. Suei, A. Taguchi, and K. Tanimoto
Diagnostic points and possible origin of osteomyelitis in synovitis, acne, pustulosis, hyperostosis and osteitis (SAPHO) syndrome: a radiographic study of 77 mandibular osteomyelitis cases
Rheumatology, November 1, 2003; 42(11): 1398 - 1403.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.